Genetic and proteomic characterization of rifaximin resistance in Bifidobacterium infantis BI07

Beatrice Vitali1, Silvia Turroni, Fabrizio Dal Piaz

  • 1Department of Pharmaceutical Sciences, CIRB-center for Biotechnology, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy.

Insights

Investigating rifaximin resistance in Bifidobacterium infantis BI07 revealed a specific gene mutation. This finding impacts the use of antibiotic-probiotic combinations for intestinal disorders.

Area of Science:

  • Microbiology
  • Genetics
  • Pharmacology

Background:

  • Antibiotic-probiotic combinations are explored for managing intestinal disorders.
  • Understanding antibiotic resistance in probiotics like Bifidobacterium infantis is crucial.

Purpose of the Study:

  • To investigate rifaximin resistance in Bifidobacterium infantis BI07.
  • To assess the implications of this resistance for antibiotic-probiotic therapy.

Main Methods:

  • Selection of a rifaximin-resistant mutant of Bifidobacterium infantis BI07.
  • Sequencing of the rpoB gene's core region to identify mutations.
  • Proteomic analysis using two-dimensional electrophoresis and mass spectrometry to study metabolic changes.
  • Liquid chromatography coupled with tandem mass spectrometry to assess drug inactivation.

Main Results:

  • A miss-sense mutation in codon 513 of the rpoB gene was identified, substituting Gln with Arg.
  • Proteomic analysis indicated altered expression of chaperonins, regulatory factors, and metabolic enzymes in resistant strains.
  • No evidence of rifaximin inactivation by bacterial enzymatic activities was found.

Conclusions:

  • A specific mutation in the rpoB gene confers rifaximin resistance in Bifidobacterium infantis BI07.
  • Metabolic changes accompany rifaximin resistance, affecting protein expression.
  • Rifaximin resistance in this probiotic is not due to drug inactivation by bacterial enzymes.

Related Concept Videos

Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...